The Oncology Journal Club Episode 18

Pinterest LinkedIn Tumblr +

Find out why coffee is so good for you and hear the team sing Baby Shark in Episode 18 of The Oncology Journal Club!

Eva Segelov gets us started with a updated guidelines on Cervical Cancer Screening, Craig Underhill talks us through a Spatio-Temporal Analysis of Guideline-Concordant Lung Cancer Treatment and Hans Prenen gets stuck into the detail of the KEYNOTE-062 trial.

You’ll also find out why coffee is so good for you and where else will you hear Hans Prenen singing Baby Shark? Yes, Eva and Craig join in too!

With the usual top quality banter, papers you won’t hear anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.

This Week’s Papers:

  1. Wah, W., et al. Association between Receipt of Guideline-Concordant Lung Cancer Treatment and Individual- and Area-Level Factors: A Spatio-Temporal Analysis. Cancer Epidemiol Biomarkers Prev October 21 2020 DOI: 10.1158/1055-9965.EPI-20-0709. Access online here.
  2. Fontham, E. T. H., et al. Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society. CA: A Cancer Journal for Clinicians. Volume 70, Issue 5, September/October 2020. Access online here.
  3. Shitara K., et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571–1580. Access online here.
  4. Kneebone, A., et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. The Lancet Oncology.  Vol 21, Issue 10P1331-1340, October 01, 2020. Access online here.
  5. Friedlaender A, et al. Tracking the tail. Journal for ImmunoTherapy of Cancer 2020;8:e000971. doi:10.1136/jitc-2020-000971. Access online here.

Quick Bites:

  1. Mackintosh C., et al. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020;6(11):1713–1721. Access online here.
  2. Pelster, M.S., et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. Journal of Clinical Oncology. Published online October 30, 2020. Access online here.
  3. Lei, J., et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383:1340-1348. Access online here.
  4. Singer R,. et al. The Baby Shark (Songs Heard Affecting Resuscitation Kinetics) study. 

Other Podcasts Discussed:

ESMO Special Edition 1

The OJC Meets Steve Vogl

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.


Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.



Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.